An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Active autoimmune cytopenia
Relapsed/refractory after ≥1 prior treatment
Body weight ≥ 55 kg
Willing to comply with and study requirements and procedures
Previous treatment with a BCMA-targeted therapy
Clinically significant infection within 3 months of screening
Major surgery or splenectomy within 3 months of screening or planned during the study
Pregnant or breastfeeding